Back to Search
Start Over
Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.
- Source :
-
Cancer [Cancer] 2012 Feb 15; Vol. 118 (4), pp. 1014-22. Date of Electronic Publication: 2011 Jul 14. - Publication Year :
- 2012
-
Abstract
- Background: The efficacy of azacitidine for the treatment of high-risk myelodysplastic syndromes has prompted the issue of its potential role even in the treatment of acute myeloid leukemia (AML).<br />Methods: The authors analyzed 82 patients with AML who were diagnosed according to World Health Organization criteria. The median patient age was 72 years (range, 29-87 years), and 27 patients (33%) had secondary AML. Of 62 patients with evaluable cytogenetics, 18 patients (29%) had a poor-risk karyotype, and 44 patients (71%) had an intermediate karyotype. Thirty-five patients (43%) received azacitidine as front-line treatment, and 47 patients (57%) had previously received 1 or more line of chemotherapy.<br />Results: The overall response rate was 32% (26 of 82 patients) and included 12 (15%) complete remissions (CRs), 4 (5%) CRs with incomplete blood count recovery (CRi), and 10 (12%) partial responses (PRs). Responses were observed more frequently among untreated patients compared with pretreated patients; in fact, 17 of 35 untreated patients (48%) responded, including 11 responses (31%) classified as CR/CRi. Conversely, only 9 of 47 pretreated patients (19%) responded, including 5 responses (11%) that were classified as CR/Cri. The response rate was significantly higher for untreated patients (P = .006) and those who had white blood cell counts <10 × 10(9) /L (P = .006). For untreated patients who achieved a response, the median overall response duration was 13 months, and the 1-year and 2-years overall survival rates were 58% and 24%, respectively.<br />Conclusions: The current results indicated that azacitidine promises to be an effective therapy for elderly patients with untreated AML and with white blood cell counts <10 × 10(9) /L.<br /> (Copyright © 2011 American Cancer Society.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic adverse effects
Azacitidine adverse effects
Female
Humans
Italy
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute mortality
Longitudinal Studies
Male
Middle Aged
Registries
Retrospective Studies
Treatment Outcome
Antimetabolites, Antineoplastic therapeutic use
Azacitidine therapeutic use
Leukemia, Myeloid, Acute drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1097-0142
- Volume :
- 118
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 21761399
- Full Text :
- https://doi.org/10.1002/cncr.26354